Sugi Predict

Sugi Predict / Compounds / SCHEMBL10163496

SCHEMBL10163496

SCHEMBL10163496

Cn1c(=O)oc2ccc(CNC(=O)c3cc(C(=O)NCc4cccc(OC(C)(F)F)c4)n4ncc(F)c4n3)cc21

nearest known ligand 0.43

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ ADAMTS4 O75173 1/20 0.43
▸ MMP3 P08254 1/20 0.43
▸ MMP13 P45452 1/20 0.43
▸ ROCK2 O75116 1/20 0.39
▸ LMNA P02545 2/20 0.39
▸ GLS O94925 9/20 0.38
▸ ATM Q13315 1/20 0.38
▸ TP53 P04637 2/20 0.37
▸ IDO1 P14902 1/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.37
▸ MAPK1 P28482 1/20 0.36
▸ ROCK1 Q13464 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8229799 0.96 ROCK2 (0.44) ADAMTS4MMP3MMP13ROCK2GLS
SCHEMBL10163503 0.94 MMP13 (0.42) ADAMTS4MMP3MMP13LMNAATM
SCHEMBL10163505 0.91 MMP13 (0.40) ADAMTS4MMP3MMP13ROCK2LMNA
SCHEMBL10163500 0.90 ADAMTS4 (0.40) ADAMTS4MMP3MMP13LMNAATM
SCHEMBL8226602 0.89 MMP13 (0.42) ADAMTS4MMP3MMP13ROCK2LMNA
SCHEMBL8225568 0.89 MMP13 (0.43) ADAMTS4MMP3MMP13ROCK2TP53
SCHEMBL10163488 0.89 MMP13 (0.44) ADAMTS4MMP3MMP13LMNATP53
SCHEMBL10162869 0.88 ROCK2 (0.41) ROCK2LMNAGLSATMTP53
SCHEMBL10163455 0.88 POLB (0.45) ADAMTS4MMP3MMP13LMNATP53
SCHEMBL10163536 0.88 MMP13 (0.44) ADAMTS4MMP3MMP13LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835441-B2 Heterobicyclic metalloprotease inhibitors AMGEN INC. (US) 2014-09-16 — — US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 — — US disclosed
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 — — US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 — — US disclosed
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2009-05-28 — — US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors MMP13, TIMP3, MMP3 ADAMTS4 38/4885MMP3 3/4885MMP13 1/4885
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 ADAMTS4 38/4885MMP3 3/4885MMP13 1/4885
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 ADAMTS4 38/4885MMP3 3/4885MMP13 1/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 ADAMTS4 38/4885MMP3 3/4885MMP13 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.